Budesonide rectal foam - Dr Falk Pharma

Drug Profile

Budesonide rectal foam - Dr Falk Pharma

Alternative Names: AJG511; Budenofalk Foam; Rectabul; Uceris Foam

Latest Information Update: 18 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dr Falk Pharma
  • Developer Dr Falk Pharma; EA Pharma; Salix Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ulcerative colitis; Ulcerative proctitis
  • Discontinued Proctitis

Most Recent Events

  • 07 Dec 2017 Launched for Ulcerative colitis in Japan (Rectal)
  • 27 Sep 2017 Registered for Ulcerative colitis in Japan (Rectal) (Eisai pipeline, November 2017)
  • 28 Oct 2016 Preregistration for Ulcerative colitis in Japan (Rectal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top